GBM Radiation Therapy + Temozolomide + Pembro + Tumor Vaccine

17C0034: A Randomized Double Blind Phase II trial of Surgery, Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in patients with newly diagnosed Glioblastoma (GBM)

  • Clinical Trial Information

    Trial Contact: Manchola-Orozco, Carolina; Walton, Sherri

    Trial Phone: 321.841.7293 ; 321.841.1907

  • IRB No: 17.066.06

    Protocol Abbrev: GBM Pembro HSPPC

    Principal Investigator: Nicholas G. Avgeropoulos, MD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: 17C0034 GBM Pembro HSPPC

    Treatment: Pembrolizumab,HSPPC-96,Temozolomide,Radiation

    Therapies Involved: Medication; Oncology: 1st line ID: NCT03018288

  • Objective

    To see if the adding pembrolizumab and HSPPC-96 improves the standard treatment for glioblastoma multiforme

  • Key Eligibility

    Adults at least 18 years old with glioblastoma